Ajinomoto Co., Inc. · TSE:2802
Ajinomoto — Investor Presentation (June 2017)
25 slides from Ajinomoto's investor presentation, Jun 8, 2017
Slide 1: Ajinomoto's Pharma-related Business employing Leading-Edge Bioscience and Fine Chemical Technologies
Ajinomoto’s Pharma-related Business employing Leading-Edge Bioscience and Fine Chemical Technologies June 8, 2017 Hiroshi Fukushi Member of the Board & Corporate Senior Vice President General Manager, AminoScience Division Copyright © 2017 Ajinomoto Co., Inc. All rights reserved.
Slide 2: The Segment I Will Talk About Today
The Segment I Will Talk About Today Genuine Global Specialty Company The Ajinomoto Group Creating Shared Value (ASV) Food Products AminoScience Japan Food Life Support (Highly Functional Materials, Products Animal Nutrition) Integrated Intl. Food Food Solutions Healthcare (Advanced Biopharma, etc.)
Slide 3: What are "Advanced Bio Pharma related business" as Defined by Ajinomoto Co.?
What are “Advanced Bio Pharma related business” as Defined by Ajinomoto Co.? Advanced Bio: Biomaterials, such as amino acids, peptides and proteins, and the application of their manufacturing technology; areas in which we have expertise Pharma-related business: Production of pharmaceuticals, materia
Slide 4: Evolution of "Advanced Bio Pharma-related business" in Ajinomoto Co.
Evolution of “Advanced Bio Pharma-related business” in Ajinomoto Co. Provision of high value-added Expansion into the field of contract manufacturing and 2. Regenerative regenerative medicine, including services using leading-edge 1. Biopharmaceuticals the field of cell therapy medicine bioscience a
Slide 5: Market Size of the Pharmaceutical Field that Ajinomoto Co. is Focused on
Market Size of the Pharmaceutical Field that Ajinomoto Co. is Focused on (1. Biopharmaceuticals 2. Regenerative medicine) 1. The entire biopharmaceutical and pharmaceutical market 2. Regenerative medicine-related market 1. Biopharmaceuticals Growth rate of ≥ 10% per year ($ billion) （億円） (¥ billion)
Slide 6: Changes in Pharmaceutical Industry Business Structure
Changes in Pharmaceutical Industry Business Structure Outsourcing in Major Pharmaceutical Companies in Japan by Process Packaging, With increased sophistication in Outsourcing rate (%) etc. development and manufacturing Formulation technology of intermediates, API and formulation, etc., the pharmace
Slide 7: Changes in Pharmaceutical Industry Business Structure
Changes in Pharmaceutical Industry Business Structure Outsourcing in Major Pharmaceutical Companies in Japan by Process Packaging, With increased sophistication in Outsourcing rate (%) etc. development and manufacturing Formulation technology of intermediates, API and formulation, etc., the pharmace
Slide 8: Activities in Each Business Field
Activities in Each Business Field Business category Initiative Organization FY17 FY18 FY19 1. Biopharmaceuticals Enter ADC contract Profit Prior investment manufacturing business contribution Ajinomoto Antibodies, Althea, Inc. recombinant proteins, Strengthen Fill & Finish Steady growth (revenue bas
Slide 9: Activities in Each Business Field
Activities in Each Business Field Business category Initiative Organization FY17 FY18 FY19 1. Biopharmaceuticals Enter ADC contract Profit Prior investment manufacturing business contribution Ajinomoto Antibodies, Althea, Inc. recombinant proteins, Strengthen Fill & Finish Steady growth (revenue bas
Slide 10: Ajinomoto Althea, Inc. which Handles the Biopharmaceutical Contract Business
Ajinomoto Althea, Inc. which Handles the Biopharmaceutical Contract Business Althea Technologies Inc. (Currently Ajinomoto Althea, Inc.) acquired in April 2013 Acquisition price (approx. ¥16 billion) Main businesses San Diego • Contract aseptic filling and packaging of biopharmaceuticals (Fill & Fin
Slide 11: Enter ADC Contract Manufacturing Business: What is "ADC"?
Enter ADC Contract Manufacturing Business: What is “ADC”? ADC: Antibody Drug Conjugate Antibody: A molecule that specifically recognizes and binds to a specific protein, etc. Some antibodies recognize cancer cells. Drug: A compound that exhibits a pharmacological action Advantages Disadvantages Anti
Slide 12: Enter ADC Contract Manufacturing Business
Enter ADC Contract Manufacturing Business Antibody manufacturing process Image of the Antibody-drug Filling process Formulation manufacturing conjugate process Fill & Finish process Drug manufacturing process Sector contracted to Ajinomoto Althea, Inc. Provision of contract manufacturing and service
Slide 13: Strengthening of the Fill & Finish Business in Ajinomoto Althea, Inc.
Strengthening of the Fill & Finish Business in Ajinomoto Althea, Inc. What is Fill & Finish? Process at the final stage of biopharmaceutical manufacture in which the product is filled aseptically into vials and syringes to become the final product. Flexible facilities allowing production of a wide v
Slide 14: Activities in Each Business Field
Activities in Each Business Field Business category Initiative Organization FY17 FY18 FY19 1. Biopharmaceuticals Enter ADC contract Profit Prior investment manufacturing business contribution Ajinomoto Antibodies, Althea, Inc. recombinant proteins, Strengthen Fill & Finish Steady growth (revenue bas
Slide 15: What are Oligonucleotides?
What are Oligonucleotides? Main Target Diseases Characteristics Structure Our Strengths Oligonucleotides Applicable to a wide range Their targets and A chain of several to A field in which we can fully of diseases including cancer, mechanisms of over a hundred utilize our wealth of cardiovascular di
Slide 16: What is AJIPHASE Technology?
What is AJIPHASE® Technology? Solid phase synthesis Dedicated oligonucleotide General chemical synthesis equipment required equipment can be used Manufacturing equipment Manufacturing Several kg/lot Several hundred kg/lot scale Development period Quick Longer than solid phase synthesis Establish AJI
Slide 17: Strengthening of the Oligonucleotide Business
Strengthening of the Oligonucleotide Business All shares in GeneDesign, Inc. were acquired in December 2016 Ajinomoto Group GeneDesign, Inc. (AJIPHASE®) Solid Phase Synthesis Speedily provides high-mix, low- The only practical technology capable volume items of mass production Flexibly handles
Slide 18: Activities in Each Business Field
Activities in Each Business Field Business category Initiative Organization FY17 FY18 FY19 1. Biopharmaceuticals Enter ADC contract Profit Prior investment manufacturing business contribution Ajinomoto Antibodies, Althea, Inc. recombinant proteins, Strengthen Fill & Finish Steady growth (earnings fo
Slide 19: Regenerative Medicine: What is a Stem Cell Culture Medium?
Regenerative Medicine What is a Stem Cell Culture Medium? A stem cell culture medium contains a well-balanced mix of amino acids, sugars, lipids, vitamins, minerals and growth factors* necessary for stem cells. Absorb nutrients Grow Human body Maintain healthy life Absorb nutrients from food Mineral
Slide 20: Requirements for Stem Cell Culture Medium Used in Regenerative Medicine
Requirements for Stem Cell Culture Medium Used in Regenerative Medicine Issues for development of stem cell culture medium for regenerative medicine 1. Performance → There are no high-performance culture media that can be used in regenerative medicine! 2. Safety → The majority of existing medium use
Slide 21: Image of the Application of iPS Cells for Regenerative Medicine
Image of the Application of iPS Cells for Regenerative Medicine Treatment for age-related macular Differentiation into degeneration, etc. retinal cells iPS cells Differentiation into Establishment Propagate cardiomyocytes Treatment for of iPS cells iPS cells heart failure, etc. Differentiation into
Slide 22: Development of Stem Cell Culture Medium for Regenerative Medicine
Development of Stem Cell Culture Medium for Regenerative Medicine Ajinomoto Co., Inc. Center for iPS Cell Research and • Research on amino acid nutrition and metabolism Application, Kyoto University (CiRA) • Analysis technology Amino acid analysis technology: Amino Index® • Novel research relating t
Slide 23: Global Expansion of StemFit Cell Culture Medium for Regenerative Medicine
Global Expansion of StemFit® Cell Culture Medium for Regenerative Medicine Products for the Japanese market For clinical research Confirmed by the PMDA* for clinical StemFit® AK03N research purposes Direct sales commenced in December 2015 by Ajinomoto Healthy Supply Co., Inc. *PMDA: Pharmaceutic
Slide 24: Realization of ASV (Ajinomoto Shared Value) through Healthcare
Realization of ASV(Ajinomoto Shared Value) through Healthcare "Genuine Global Specialty Company" To become a global top 10 class company that grows sustainably through ASV Integrated Value Corporate Brand Enhance brand value through creating social/economic value, which leads to further value creati
Slide 25: Copyright © 2017 Ajinomoto Co., Inc. All rights reserved.
Copyright © 2017 Ajinomoto Co., Inc. All rights reserved. 24